KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) EBIT (2016 - 2025)

CRISPR Therapeutics AG's EBIT history spans 11 years, with the latest figure at -$154.8 million for Q4 2025.

  • For Q4 2025, EBIT fell 139.62% year-over-year to -$154.8 million; the TTM value through Dec 2025 reached -$664.6 million, down 42.44%, while the annual FY2025 figure was -$664.6 million, 42.44% down from the prior year.
  • EBIT for Q4 2025 was -$154.8 million at CRISPR Therapeutics AG, down from -$132.1 million in the prior quarter.
  • Across five years, EBIT topped out at $762.6 million in Q2 2021 and bottomed at -$229.3 million in Q2 2025.
  • The 5-year median for EBIT is -$132.2 million (2023), against an average of -$82.7 million.
  • The largest annual shift saw EBIT surged 1045.13% in 2021 before it crashed 192.82% in 2024.
  • A 5-year view of EBIT shows it stood at -$145.7 million in 2021, then grew by 9.72% to -$131.5 million in 2022, then surged by 152.9% to $69.6 million in 2023, then plummeted by 192.82% to -$64.6 million in 2024, then plummeted by 139.62% to -$154.8 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's EBIT are -$154.8 million (Q4 2025), -$132.1 million (Q3 2025), and -$229.3 million (Q2 2025).